Chiara Cupidi

Chiara Cupidi

Auto-generated profile, based on publicly available information

Chiara Cupidi

Regional Neurogenetic Centre (CRN), ASP Catanzaro, Lamezia Terme, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2017 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RSRebecca Sims
Rebecca Sims
SLSven J van der Lee
Sven J van der Lee
ANAdam C Naj
Adam C Naj
CBCéline Bellenguez
Céline Bellenguez
NBNandini Badarinarayan
Nandini Badarinarayan
GSGerard D Schellenberg
Gerard D Schellenberg

1 July 2014 in The Lancet Neurology
Verified
Journal Article
Closed access
RFRaffaele Ferrari
Raffaele Ferrari
DHDena G Hernandez
Dena G Hernandez
MNMichael A Nalls
Michael A Nalls
JRJonathan D Rohrer
Jonathan D Rohrer
ARAdaikalavan Ramasamy
Adaikalavan Ramasamy
PMParastoo Momeni
Parastoo Momeni

1 September 2013 in Biological Psychiatry
Verified
Journal Article
Closed access
DGDaniela Galimberti
Daniela Galimberti
CFChiara Fenoglio
Chiara Fenoglio
MSMaria Serpente
Maria Serpente
Chiara VillaChiara Villa
Chiara Villa
RBRossana Bonsi
Rossana Bonsi
ESElio Scarpini
Elio Scarpini

1 August 2010 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
OBOrso Bugiani
Orso Bugiani
GGgiorgio giaccone
giorgio giaccone
GRGiacomina Rossi
Giacomina Rossi
MMMichela Mangieri
Michela Mangieri
RCRaffaella Capobianco
Raffaella Capobianco
FTFabrizio Tagliavini
Fabrizio Tagliavini
The most common form of cerebral amyloid angiopathy (CAA) is due to the accumulation of amyloid-β peptide (Aβ) within the walls of small cerebral vessels.1-3 Amyloid makes vessel walls prone to rupture and narrows their lumina to the point of occlusion, thus explaining secondary lesions as intracerebral and subarachnoid bleeding, multiple infarcts, and periventricular edema. Cerebral amyloid angiopathy induced by Aβ (Aβ-CAA) occurs during aging and in Alzheimer disease (AD). Most elderly people are asymptomatic carriers of Aβ-CAA.4,5 In AD patients, Aβ-CAA may contribute to cognitive impairment by adding vascular lesions to neurodegeneration. The burden of Aβ-CAA varies widely, but has been found to be marked in a subset of patients with sporadic AD6,7 and in familial AD due to duplication of the APP locus8 and to mutations of APP,9-13PS1,14 and PS2.15

1 June 2012 in International Psychogeriatrics
Verified
Journal Article
Open access
PDF file
CCChiara Cupidi
Chiara Cupidi
SRSabrina Realmuto
Sabrina Realmuto
Gianluca Lo CocoGianluca Lo Coco
Gianluca Lo Coco
ACAntonio Cinturino
Antonio Cinturino
STSimona Talamanca
Simona Talamanca
DCDaniele Lo Coco
Daniele Lo Coco
Background: Knowledge about sleep complaints of caregivers of patients with Alzheimer's disease (AD) and Parkinson's disease (PD) is limited, and we lack information about the relationship between caregivers’ sleep problems and their quality of life (QoL). Methods: We evaluated subjective sleep quality and its relationship to QoL in a group of 80 caregivers of patients with AD (ADCG, n = 40) and PD (PDCG, n = 40), and in 150 controls. Information about night-time complaints was collected using the Pittsburgh Sleep Quality Index (PSQI). QoL was measured using the McGill QoL Questionnaire. Results: Eighteen ADCG (45%), 22 PDCG (55%), and 45 (30%) controls reported poor sleep quality. Mean global PSQI score of PDCG (6.25 ± 3.9) was not significantly different from that of ADCG (5.8 ± 3.5; p = 0.67). However, both PDCG and ADCG scored significantly higher than control group (4.3 ± 3.1; p < 0.01). ADCG frequently reported difficulties falling asleep (72.5%) and disturbed sleep (100%). PDCG reported reduced subjective sleep quality (80%) and increased sleep disturbances (100%). Poor sleep quality was associated with depressive symptoms and correlated with QoL in caregivers of both groups, particularly the psychological symptoms domain. Conclusions: Among caregivers of patients with AD and PD, poor sleep quality is frequent and significantly linked to QoL and depressive symptoms. Identifying the nature of sleep disturbances not only in patients but also in their caregivers is important as appropriate treatment may lead to a better management of the needs of families coping with these patients.

13 April 2016 in Aging Cell
Verified
Journal Article
Open access
PDF file
Viviana TriacaViviana Triaca
Viviana Triaca
VSValentina Sposato
Valentina Sposato
GBGiulia Bolasco
Giulia Bolasco
MCMaria Teresa Ciotti
Maria Teresa Ciotti
PPPiergiuseppe Pelicci
Piergiuseppe Pelicci
PCPietro Calissano
Pietro Calissano
NGF has been implicated in forebrain neuroprotection from amyloidogenesis and Alzheimer's disease (AD). However, the underlying molecular mechanisms are still poorly understood. Here, we investigated the role of NGF signalling in the metabolism of amyloid precursor protein (APP) in forebrain neurons using primary cultures of septal neurons and acute septo-hippocampal brain slices. In this study, we show that NGF controls the basal level of APP phosphorylation at Thr668 (T668) by downregulating the activity of the Ser/Thr kinase JNK(p54) through the Tyr kinase signalling adaptor SH2-containing sequence C (ShcC). We also found that the specific NGF receptor, Tyr kinase A (TrkA), which is known to bind to APP, fails to interact with the fraction of APP molecules phosphorylated at T668 (APP(pT668) ). Accordingly, the amount of TrkA bound to APP is significantly reduced in the hippocampus of ShcC KO mice and of patients with AD in which elevated APP(pT668) levels are detected. NGF promotes TrkA binding to APP and APP trafficking to the Golgi, where APP-BACE interaction is hindered, finally resulting in reduced generation of sAPPβ, CTFβ and amyloid-beta (1-42). These results demonstrate that NGF signalling directly controls basal APP phosphorylation, subcellular localization and BACE cleavage, and pave the way for novel approaches specifically targeting ShcC signalling and/or the APP-TrkA interaction in AD therapy.